Compare AU

Compare CURE vs. VTS

Compare shares and ETFs on the ASX that you can trade on Pearler.

S&P US Biotech

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US Biotech (CURE) and the US Total Market (VTS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

VTS

Popularity

Low

Medium

Pearlers invested

83

2,879

Median incremental investment

$619.50

$1,271.76

Median investment frequency

Monthly

Monthly

Median total investment

$1,461.60

$5,178.36

Average age group

> 35

> 35


Key Summary

CURE

VTS

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Vanguard U.S. Total Market Shares Index ETF (ASX: VTS) seeks to track the performance of the CRSP US Total Market Index before account fees, expenses and taxes. The index tracks the large, mid, small and micro-cap stocks on the US stock market, thus representing nearly 100% of the investable US stock market.

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Apple Inc. (5.56 %)

Microsoft Corp. (4.68 %)

Amazon.com Inc. (2.06 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Information Technology (25.02 %)

Health Care (15.04 %)

Financials (10.84 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

United States (99.41 %)

Switzerland (0.25 %)

Canada (0.12 %)

Management fee

0.45 %

0.03 %


Key Summary

CURE

VTS

Issuer

Global X

Vanguard

Tracking index

S&P Biotechnology Select Industry

CRSP U.S. Total Market Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.03 %

Price

$52.32

$470.23

Size

$36.301 million

$29.146 million

10Y return

N/A

273.20 %

Annual distribution yield (5Y)

4.24 %

1.34 %

Market

ASX

ASX

First listed date

12/11/2018

08/05/2009

Purchase fee

$6.50

$6.50


Community Stats

CURE

VTS

Popularity

Low

Medium

Pearlers invested

83

2,879

Median incremental investment

$619.50

$1,271.76

Median investment frequency

Monthly

Monthly

Median total investment

$1,461.60

$5,178.36

Average age group

> 35

> 35


Pros and Cons

CURE

VTS

Pros

  • Higher distribution yield

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

CURE

VTS

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home